Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.05
- Piotroski Score 2.00
- Grade Neutral
- Symbol (VTYX)
- Company Ventyx Biosciences, Inc.
- Price $1.73
- Changes Percentage (0.58%)
- Change $0.01
- Day Low $1.67
- Day High $1.77
- Year High $11.48
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $45.00
- High Stock Price Target $60.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.24
- Trailing P/E Ratio -1.01
- Forward P/E Ratio -1.01
- P/E Growth -1.01
- Net Income $-192,962,000
Income Statement
Quarterly
Annual
Latest News of VTYX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures
Ownership data and analyst forecasts provide insight into a company's potential. For Ventyx Biosciences, institutional investors hold a significant stake, influencing stock price movements. Shareholde...
By Yahoo! Finance | 4 days ago -
Ventyx Biosciences, Inc. (VTYX) Stock Price, News, Quote & History - Yahoo Finance
Kenny Rogers' song "The Gambler" highlights the balance between risk and reward, a key lesson for investors. Penny stocks, trading at $5 or less, offer high potential returns but also high risk. Inves...
By Yahoo! Finance | 3 weeks ago -
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?
A company's lack of profitability does not always lead to a stock decline, as seen with Salesforce.com. However, the risk of cash burn is crucial. Ventyx Biosciences, with increasing cash burn, faces ...
By Yahoo! Finance | 4 months ago
